Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522
September 17, 2018 07:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
August 08, 2018 16:03 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates
August 08, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Partial Clinical Hold for XMT-1522 Clinical Trial
July 19, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc.(NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018
June 04, 2018 09:01 ET
|
Mersana Therapeutics, Inc.
Favorable Tolerability Profile and Early Signs of Efficacy Demonstrated First Disclosure of Clinical Data from Novel Dolaflexin Platform Mersana To Host Conference Call and Webcast Including...
Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference
May 31, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting
May 22, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces First Quarter 2018 Financial Results and Provides Business Updates
May 14, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
Phase 1 Dose Escalation Trials Progressing for Lead Programs XMT-1522 and XMT-1536 Presented Data of Dolaflexin® Platform Unique DolaLock Technology and XMT-1522 Synergy with a Checkpoint Inhibitor...
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates
May 07, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
May 01, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...